For decades, the science of extending human life has been rich in laboratory breakthroughs but poor in real-world human proof. Mice have lived longer, and cellular pathways have been optimized in lab settings, yet translating these findings into actionable medicine for humans has remained frustratingly out of reach. That is officially changing. UT Health San Antonio's Sam and Ann Barshop Institute has announced the VITAL-H longevity trial, a historic initiative designed to see if medicines already sitting in our pharmacy cabinets can stall the biological clock.

Backed by up to $38 million from the Advanced Research Projects Agency for Health (ARPA-H), this trial represents one of the most significant human longevity clinical trials 2026 has to offer. It serves as a cornerstone of ARPA-H's PROSPR program, which is funneling $144 million across seven institutions to accelerate healthy aging breakthroughs. Instead of hunting for an entirely new experimental compound, researchers are testing three FDA-approved medications to see if they can preserve human healthspan—the years we live free of debilitating disease.

A $38 Million Bet on Human Healthspan

The study, formally named Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H), is poised to enroll 726 generally healthy adults between the ages of 60 and 65. Led by Dr. Elena Volpi, director of the Barshop Institute, the project acts as the culmination of 50 years of UT Health San Antonio aging research.

Rather than exclusively targeting a single condition like Alzheimer's or cancer, the VITAL-H trial treats aging as a modifiable biological trajectory. If successful, it could provide the first rigorous regulatory proof that pharmaceutical interventions can delay multiple age-related declines simultaneously. The trial will intentionally focus heavily on recruiting from South Texas, aiming to bring Hispanic communities—who are historically underrepresented in clinical research—into the fold of cutting-edge healthy aging breakthroughs. Giving diverse populations the opportunity to participate ensures that longevity medicine does not become an exclusive aspiration, but rather a widespread clinical reality.

The Three Anti-Aging Contenders: Ozempic, Rapamycin, and Dapagliflozin

To determine if we already possess drugs to slow biological aging, the VITAL-H study will divide participants into four groups: three testing distinct medications and one receiving a placebo. The selected drugs arrive with varying reputations, but all share compelling mechanisms that influence cellular aging.

Rapamycin: The Anti-Aging Veteran

Originally approved in 1999 as an immunosuppressant for organ transplants, Rapamycin gained near-mythic status in aging circles after a landmark 2009 Barshop study proved it extended the lifespan of mice. This upcoming Rapamycin healthspan study will be one of the first to rigorously examine if those celebrated mammalian results translate into preserved physical and mental function in aging humans, moving beyond earlier mixed results observed in marmoset monkeys.

Semaglutide: The 'Ozempic of Longevity'

Semaglutide, the wildly popular GLP-1 receptor agonist sold under brand names like Ozempic and Wegovy, is best known for diabetes management and weight loss. However, researchers are increasingly looking at Ozempic for anti-aging. Recent data links GLP-1 drugs to broad systemic benefits, including reduced cardiovascular risk and improvements in chronic kidney disease. The core question researchers want to answer is whether these benefits stem merely from weight loss or from a direct impact on the deeper biological systems involved in aging.

Dapagliflozin: Fighting 'Inflammaging'

While less famous than Ozempic, Dapagliflozin (sold as Farxiga) is a powerful contender in the longevity race. It is an SGLT2 inhibitor that helps kidneys flush excess glucose through urine to treat Type 2 diabetes. Fascinatingly, researchers note that it also appears to influence the underlying biology connecting aging to chronic disease. Specifically, it lowers low-grade chronic inflammation—a slow, corrosive biological stress heavily linked to physical decline, often dubbed "inflammaging".

Measuring 'Intrinsic Capacity' Instead of Lifespan

Proving that a drug extends human lifespan would technically require decades of waiting. To make the science actionable now, researchers are adopting a metric developed by the World Health Organization called "intrinsic capacity".

Intrinsic capacity shifts the focus away from counting birthdays and toward measuring everyday functionality. Researchers will ask the harder questions: Can you still move freely? Are you sleeping well? Is your cognition sharp?. By tracking five functional domains over three years—along with an additional six months of follow-up once participants stop taking the medications—the team hopes to capture definitive proof of delayed biological decline. Participants will wear Oura rings to monitor physical activity and sleep, and utilize a decentralized hybrid model for easy, continuous assessments. Data will be shared with performer teams at Stanford University, Columbia University, and the Buck Institute to ensure the FDA views intrinsic capacity as a valid, regulatory-grade endpoint.

The Future of Healthy Aging Breakthroughs

For a sector frequently criticized for peddling overhyped biohacking trends, the VITAL-H longevity trial offers a deeply grounded approach to medicine. By repurposing established, FDA-approved medications, we bypass the decades-long safety testing required for entirely novel compounds.

Dr. Volpi and the UT Health San Antonio team are not chasing immortality. Their goal is far more pragmatic and universally desired: condensing the years of disease and disability at the end of life. If Rapamycin, Semaglutide, or Dapagliflozin prove successful, the first true prescription for an extended human healthspan may already be waiting at your local pharmacy.